Omics : a journal of integrative biologyOct 21, 2026

Comparing Oral and Injectable Incretin-Based Weight Loss Treatments: A Combined Data Analysis of Orforglipron, Semaglutide, and Tirzepatide

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Oct 22, 2026

Abstract

Tirzepatide produced 20.2% weight loss compared to 13.7% with semaglutide at week 72 in head-to-head trials.

Orforglipron, an oral GLP-1 receptor agonist, completed phase 3 testing, allowing for comparison with injectable agents.
Molecular descriptors and a comprehensive drug-target-disease network were utilized to evaluate treatment options.
Tirzepatide was ranked highest in effectiveness and safety under multiple decision-making models after addressing an ADMET score issue.
Orforglipron's design suggests enhanced oral absorption capabilities, contributing to its high ranking in accessibility-focused models.
Tirzepatide's cardiovascular safety profile was supported by data from the SURPASS-CVOT trial, showing non-inferiority to dulaglutide.
No single medication was superior across all evaluation criteria; treatment choices should align with individual patient priorities.

Simplified

Incretin-based agents are transforming obesity pharmacotherapy, and orforglipron, the first oral non-peptide GLP-1 receptor agonist to complete phase 3 testing, invites direct comparison with the injectable agents semaglutide and tirzepatide. We integrated clinical trial evidence, including the direct head-to-head SURMOUNT-5 trial, independently verified molecular descriptors, a fully specified drug-target-disease network with permutation-tested hub significance, hypergeometric pathway enrichment, and multi-criteria decision analysis (MCDA) across four weighting schemes with formal sensitivity analysis. Tirzepatide produced significantly greater weight loss than semaglutide under randomized, head-to-head conditions (20.2% vs. 13.7% at week 72) and ranked highest under balanced, efficacy-, and safety-dominant MCDA models once a composite ADMET score misapplied to two large peptides was removed. Orforglipron's lipophilicity exceeds the Lipinski ceiling, showing that its oral absorption reflects deliberate chemistry rather than default small-molecule developability; it nonetheless ranked highest under an accessibility-dominant model driven by oral feasibility and manufacturing scalability. These rankings were stable under Monte Carlo sensitivity analysis for three of four weighting schemes, with the balanced model comparatively fragile. Tirzepatide's cardiovascular evidence has also advanced, with SURPASS-CVOT reporting non-inferiority to dulaglutide. No single agent dominates every criterion; treatment selection should match the clinical priority the individual patient weights most heavily.

Full Text

Full text is available at the source.

View Full Text ↗

Comparing Oral and Injectable Incretin-Based Weight Loss Treatments: A Combined Data Analysis of Orforglipron, Semaglutide, and Tirzepatide

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief